ArticleMolecular and clinical oncology2019

Bevacizumab in the neoadjuvant treatment of human epidermal growth factor receptor 2-negative breast cancer: A meta-analysis of randomized controlled trials.

Zeina Nahleh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.